The Cellular Composition of the Tumor Microenvironment is an Important Marker for Predicting Therapeutic Efficacy in Breast Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Mar 15

PMID 38487526

Authors

Tingyao Dou

Jing Li

Yaochen Zhang

Wanru Pei

Binyue Zhang

Bin Wang

Yanhong Wang

Hongyan Jia

Affiliations

Soon will be listed here.

Abstract

At present, the incidence rate of breast cancer ranks first among new-onset malignant tumors in women. The tumor microenvironment is a hot topic in tumor research. There are abundant cells in the tumor microenvironment that play a protumor or antitumor role in breast cancer. During the treatment of breast cancer, different cells have different influences on the therapeutic response. And after treatment, the cellular composition in the tumor microenvironment will change too. In this review, we summarize the interactions between different cell compositions (such as immune cells, fibroblasts, endothelial cells, and adipocytes) in the tumor microenvironment and the treatment mechanism of breast cancer. We believe that detecting the cellular composition of the tumor microenvironment is able to predict the therapeutic efficacy of treatments for breast cancer and benefit to combination administration of breast cancer.

Citing Articles

Canine, Feline, and Murine Mammary Tumors as a Model for Translational Research in Breast Cancer.

Cassali G, Nakagaki K, Salvi M, Dos Reys M, Rocha M, de Campos C Vet Sci. 2025; 12(2).

PMID: 40005948 PMC: 11860833. DOI: 10.3390/vetsci12020189.

Investigating the role of cathepsins in breast cancer progression: a Mendelian randomization study.

Zhou S, Sun Y, Zha W, Zhou G Front Oncol. 2025; 15:1408723.

PMID: 39944834 PMC: 11815281. DOI: 10.3389/fonc.2025.1408723.

Single-cell mitophagy patterns within the tumor microenvironment modulate intercellular communication, impacting the progression and prognosis of hepatocellular carcinoma.

Li Z, Chen W, Yao S, Peng Z, Liu H, Tang Y Front Immunol. 2025; 15():1448878.

PMID: 39835122 PMC: 11742944. DOI: 10.3389/fimmu.2024.1448878.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Advancements in the Application of scRNA-Seq in Breast Research: A Review.

Zhang Z, Ma X, La Y, Guo X, Chu M, Bao P Int J Mol Sci. 2025; 25(24.

PMID: 39769466 PMC: 11677372. DOI: 10.3390/ijms252413706.

References

Kim H, Lee G, Sohn S, Lee C, Kwak J, Bae H . Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy. Korean J Physiol Pharmacol. 2016; 20(3):261-8. PMC: 4860368. DOI: 10.4196/kjpp.2016.20.3.261. View

Plava J, Burikova M, Cihova M, Trnkova L, Smolkova B, Babal P . Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer. J Exp Clin Cancer Res. 2021; 40(1):302. PMC: 8477536. DOI: 10.1186/s13046-021-02087-2. View

Gebhardt T, Wakim L, Eidsmo L, Reading P, Heath W, Carbone F . Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009; 10(5):524-30. DOI: 10.1038/ni.1718. View

Usman M, Gao J, Zheng T, Rui C, Li T, Bian X . Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. Cell Death Dis. 2018; 9(8):809. PMC: 6057974. DOI: 10.1038/s41419-018-0849-6. View

Bahrami A, Hassanian S, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M . The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress. J Cell Biochem. 2017; 119(1):111-122. DOI: 10.1002/jcb.26183. View

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

Julia E, Amante A, Pampena M, Mordoh J, Levy E . Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol. 2018; 9:2140. PMC: 6159755. DOI: 10.3389/fimmu.2018.02140. View

Kim H, Jung M, Choi S, Woo J, Piao Y, Hwang E . IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. J Exp Clin Cancer Res. 2018; 37(1):200. PMC: 6106749. DOI: 10.1186/s13046-018-0867-3. View

Dittmer A, Dittmer J . Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin β1. Oncotarget. 2018; 9(31):22079-22094. PMC: 5955132. DOI: 10.18632/oncotarget.25183. View

10.

Li Q, Xia J, Yao Y, Gong D, Shi H, Zhou Q . Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells. Breast Cancer Res Treat. 2013; 141(2):317-24. PMC: 3816005. DOI: 10.1007/s10549-013-2672-1. View

11.

Marrufo A, Mathew S, Chaudhary P, Malaer J, Vishwanatha J, Mathew P . Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. Am J Cancer Res. 2018; 8(6):1050-1063. PMC: 6048397. View

12.

Zahid H, Simpson E, Brown K . Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. Curr Opin Pharmacol. 2016; 31:90-96. DOI: 10.1016/j.coph.2016.11.003. View

13.

Ryan D, Paul B, Koziol J, ElShamy W . The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Breast Cancer Res. 2019; 21(1):53. PMC: 6480921. DOI: 10.1186/s13058-019-1131-2. View

14.

Maughan K, Lutterbie M, Ham P . Treatment of breast cancer. Am Fam Physician. 2010; 81(11):1339-46. View

15.

Mauri C, Bosma A . Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30:221-41. DOI: 10.1146/annurev-immunol-020711-074934. View

16.

Zhang L, Wang X, Ding J, Sun Q, Zhang S . The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Ann Diagn Pathol. 2019; 40:143-151. DOI: 10.1016/j.anndiagpath.2019.04.004. View

17.

Marusyk A, Tabassum D, Janiszewska M, Place A, Trinh A, Rozhok A . Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016; 76(22):6495-6506. PMC: 5344673. DOI: 10.1158/0008-5472.CAN-16-1457. View

18.

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

19.

De Cicco P, Ercolano G, Ianaro A . The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol. 2020; 11:1680. PMC: 7406792. DOI: 10.3389/fimmu.2020.01680. View

20.

Li J, Tsang J, Tse G . Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel). 2021; 13(16). PMC: 8394502. DOI: 10.3390/cancers13164233. View